Bisphosphonate-related osteonecrosis of the jaws: A review of 34 cases and evaluation of risk

Journal of Cranio-Maxillofacial Surgery

Volumn 38, Issue 4, 2010, Pages 255-259

  Kos, Marcin ^a   Kuebler, Joachim F ^a   Luczak, Klaudiusz ^a   Engelke, Werner ^a  

^a KLINIKUM MINDEN   (Germany)

Author keywords

bisphosphonate; jaw; osteonecrosis; osteoporosis; risk

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ACTINOMYCES; ADULT; AGED; ARTICLE; BACTERIAL COLONIZATION; BREAST CARCINOMA; CLINICAL ARTICLE; CLINICAL FEATURE; CYSTENUCLEATION; DRUG POTENCY; ENUCLEATION; FACE INJURY; FEMALE; HUMAN; JAW OSTEONECROSIS; MALE; MULTIPLE MYELOMA; ORAL SURGERY; OSTEOPOROSIS; PROSTATE CANCER; PROSTATE CARCINOMA; RETROSPECTIVE STUDY; ROOT APICOTOMY; SEX DIFFERENCE; SIDE EFFECT; TOOTH EXTRACTION; TOOTH IMPLANTATION; TOOTH PROSTHESIS; TREATMENT OUTCOME; CHEMICALLY INDUCED; DOSE RESPONSE; MANDIBULAR DISEASES; MAXILLARY DISEASES; MIDDLE AGED; NEOPLASMS; OSTEONECROSIS; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MANDIBULAR DISEASES; MAXILLARY DISEASES; MIDDLE AGED; NEOPLASMS; OSTEONECROSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TOOTH EXTRACTION;

EID: 77951975614     PISSN: 10105182     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcms.2009.06.005     Document Type: Article

References (28)

1. Abu-Id M.H., Warnke P.H., Gottschalk J., Springer I., Wiltfang J., Acil Y., Russo P.A., and Kreusch T. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 36 (2008) 95-103
2. Bamias A., Kastritis E., Bamia C., Moulopoulos L.A., Melakopoulos I., Bozas G., Koutsoukou V., Gika D., Anagnostopoulos A., Papadimitriou C., Terpos E., and Dimopoulos M.A. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23 (2005) 8580-8587
3. Chapurlat R.D., Hugueny P., Delmas P.D., and Meunier P.J. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone 35 (2004) 235-242
4. Cremers S.C., Pillai G., and Papapoulos S.E. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmcokinet 44 (2005) 551-570
5. Dimopoulos M.A., Kastritis E., Anagnostopoulos A., Melakopoulos I., Gika D., Moulopoulos L.A., Bamia C., Terpos E., Tsionos K., and Bamias A. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91 (2006) 968-971
6. Engel I.A., Straus D.J., Lacher M., Lane J., and Smith J. Osteonecrosis in patients with malignant lymphoma: a review of twenty-five cases. Cancer 48 (1981) 1245-1250
7. Ganguli A., Steward C., Butler S.L., Philips G., Meikle S.T., Lloyd A.W., and Grant M.H. Bacterial adhesion to bisphosphonate coated hydroxyapatite. J Mater Sci Mater Med 16 (2005) 283-287
8. Gutta R., Louis P.J., and Birmingham A.L. Bisphosphonates and osteonecrosis of the jaws: science and rationale. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104 (2007) 186-189
9. Lenz J.H., Steiner-Krammer B., Schmidt W., Fietkau R., Mueller P.C., and Gundlach K.K. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?. J Craniomaxillofac Surg 33 (2005) 395-403
10. Malmgren B., Astrom E., and Soderhall S. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med 37 (2008) 196-200
11. Marx R.E., Cillo Jr. J.E., and Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65 (2007) 2397-2410
12. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115-1117
13. Migliorati C.A., Schubert M.M., Peterson D.E., and Seneda L.M. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104 (2005) 83-93
14. Mirzai R., Chang C., Greenspan A., and Gershwin M.E. The pathogenesis of osteonecrosis and the relationships to corticosteroids. J Asthma 36 (1999) 77-95
15. Ortega C., Montemurro F., Faggiuolo R., Vormola R., Nanni D., Goia F.M., Gilardino M.O., and Aglietta M. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis. Acta Oncol 46 (2007) 664-668
16. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
17. Russell R.G., and Rogers M.J. Bisphosphonates: from the laboratory to the clinic and back again. Bone 25 (1999) 97-106
18. Saad F., Adachi J.D., Brown J.P., Canning L.A., Gelmon K.A., Josse R.G., and Pritchard K.I. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 26 (2008) 5465-5476
19. Schwartz H.C. Osteonecrosis and bisphosphonates: correlation versus causation. J Oral Maxillofac Surg 62 (2004) 763-764
20. Schwartz H.C. Osteonecrosis of the jaws: a complication of cancer chemotherapy. Head Neck Surg 4 (1982) 251-253
21. Schwartz S., Joseph C., Iera D., and Vu D.D. Bisphosphonates, osteonecrosis, osteogenesis imperfecta and dental extractions: a case series. J Calif Dent Assoc 74 (2008) 537-542
22. Tarassoff P., and Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 61 (2003) 1238-1239
23. Tauchmanova L., de Rosa G., and Serio B. Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: a single center experience and a review. Cancer 97 (2003) 2453-2461
24. Viellard M.H., Maes J.M., Penel G., Facon T., Magro L., Bonneterre J., and Cortet B. Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. Joint Bone Spine 75 (2008) 34-40
25. Wang E.P., Kaban L.B., Strewler G.J.M.D., Raje N., and Troulis M.J. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 65 (2007) 1328-1331
26. Woo S.B., Hellstein J.W., and Kalmar J.R. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 (2006) 753-761
27. Wu S., Dahut W.L., and Gulley J.L. The use of bisphosphonates in cancer patients. Acta Oncol 46 (2007) 581-591
28. Zervas K., Verrou E., Teleioudis Z., Vahtsevanos K., Banti A., Mihou D., Krikelis D., and Terpos E. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 134 (2006) 20-23